AstraZeneca

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

AZ bags first approval for PNH therapy danicopan, in Japan

AstraZeneca has claimed its first regulatory approval for oral Factor D inhibitor danicopan, getting a green light in Japan for the drug as Voydeya for the treatment of pa

News

Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu.

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

News

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indic

News

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infan

Trial data raises questions about Imfinzi in liver cancer

AZ bags first approval for PNH therapy danicopan, in Japan

Seagen patent in Daiichi Sankyo ADC dispute nixed by USPTO

As Novartis backs off, Amgen said to be after Cytokinetics

JPM: GSK announces $1.4bn deal to buy asthma biotech Aiolos

AZ, Sanofi’s Beyfortus cleared in China for RSV prevention

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AstraZeneca

Editor's Picks